Researchers develop AI tool to predict patients at risk of intimate partner violence

NIH-funded, automated. clinical decision support. could. facilitate. timely. interventions for. at-risk. patients. years. before they might otherwise seek help. The institutional report frames the development in practical terms and ties it to the broader mission or observing effort.

That matters because biology becomes more informative when an observed effect begins to look like a mechanism rather than an isolated pattern. The gap between identifying a correlation in biological data and understanding the causal chain that produces it is routinely underestimated, and the history of biomedical research is populated with associations that collapsed when the mechanism was sought and not found. A result that comes with a proposed mechanism, even a partial one, is more useful than a purely descriptive finding because it generates testable predictions that can narrow the hypothesis space. NIH-funded, automated clinical decision support could facilitate timely interventions for at-risk patients years before they might otherwise seek help. A team of researchers funded by the National Institutes of Health (NIH) have developed an artificial intelligence (AI) tool that provides decision support to clinicians by.

IPV refers to abuse from current or former partners that results in serious effects such as potentially life-threatening injuries, chronic pain and mental health disorders. In their study, the research team led by researchers from Harvard Medical School, Boston, introduced three AI models for IPV detection in healthcare settings, comparing their.

Qi Duan, Ph. D, director of the Division of Health Informatics Technologies at NIH’s National Institute of Biomedical Imaging and Bioengineering (NIBIB). The researchers used several years of hospital data from nearly 850 affected female patients and 5, 200 unaffected age- and demographics-matched control patients.

It performed accurately 88% of the time. About Intimate Partner Violence | Intimate Partner Violence Prevention | CDC For more about Automated IPV Risk Support: https: //bhartikhurana. bwh. harvard.

The broader interest lies in whether the reported effect points toward a real mechanism and not merely a reproducible but unexplained association. Biology has learned from decades of biomarker failures that correlation, even robust correlation, is not a substitute for mechanistic understanding. A pathway that can be traced from molecular interaction to cellular response to organismal phenotype provides a far stronger foundation for intervention than a statistical association discovered in a large dataset, however well the statistics are done.

About the National Institute of Biomedical Imaging and Bioengineering (NIBIB): NIBIB’s mission is to improve health by leading the development and accelerating the application of. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both.

Because the account originates with NIH News Releases, it functions best as a primary institutional report that is close to the data and operations, not as independent scientific validation. Institutional communications are produced by organizations with legitimate interests in presenting their work in a favorable light, which does not make them unreliable but does make them partial. Details that complicate the narrative, including instrument limitations, unexpected failures and results below projections, tend to be minimized relative to progress messages. Technical documentation and peer-reviewed publications, where they exist, provide the complementary layer that institutional releases cannot substitute.

The next step is to test whether the effect repeats across different methods, cell types, model organisms and experimental conditions. Reproducibility is the first test, but mechanistic dissection is the second, and a result that passes both has a substantially better chance of translating into something clinically or biotechnologically useful. The path from a laboratory finding to an applied outcome typically takes a decade or more, and most findings do not complete it; the current result sits at the beginning of that process.

Source